Pediatrix Medical Group, Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Pediatrix Medical Group, Inc., covering the three-month period ended March 31, 2001. The Company operates as a medical group providing neonatal, newborn, and pediatric services. As of May 4, 2001, there were 16,076,953 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Net Patient Service Revenue | $63.9 million | $59.4 million |
| Operating Expenses | $56.9 million | $52.4 million |
| Income from Operations | $7.0 million | $7.0 million |
| Net Income | $3.6 million | $3.4 million |
| Diluted EPS | $0.22 | $0.22 |
| Cash from Operating Activities | $8.2 million | $5.3 million |
| Cash and Equivalents (End of Period) | $1.8 million | $1.1 million |
| Line of Credit Outstanding | $15.8 million | $23.5 million (Dec 2000) |
| Working Capital | $8.0 million | $2.1 million (Dec 2000) |
Margins: Operating margin remained stable at approximately 11%. The effective income tax rate was 45.0%.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7.6% year-over-year. This was driven by a 4.5% increase in same-unit revenue (due to higher patient acuity) and 42.2% of the increase attributable to new units from acquisitions.
- Expense Increases: Salaries and benefits rose 7.3% due to new hires and support for regionalization. Supplies and other operating expenses increased 19.9% primarily due to rent and collection office costs.
- Interest Expense: Net interest expense decreased significantly from $907,000 to $452,000, driven by a reduction in the line of credit balance.
- Cash Flow: Net cash provided by operating activities increased to $8.2 million from $5.3 million. However, cash used in investing activities was $2.2 million (vs. $8.7 million prior year), and financing activities used $7.4 million primarily due to debt repayments.
Outlook, Risks, and Unusual Items
- Merger with Magella: On February 15, 2001, the Company signed a definitive merger agreement with Magella Healthcare Corporation. The transaction, valued at approximately $164.3 million, is expected to close on May 15, 2001, subject to shareholder approval. Pediatrix will assume approximately $25 million of Magella's bank debt and $23.5 million in convertible notes.
- Legal Contingencies:
- Class Action: A federal securities class action regarding billing practices and financial statements (filed Feb 1999) is in the discovery stage. A pre-trial conference is set for August 17, 2001. The Company believes claims are without merit but notes potential damages could exceed insurance coverage.
- Government Investigations: Investigations into Medicaid billing practices in Arizona and Florida were settled in 2000 ($260,000 total). An investigation in Colorado remains ongoing, and inquiries in other states are possible.
- Liquidity: The Company has a $75 million line of credit maturing September 30, 2001. Management is evaluating financing options for renewal but notes no assurance of obtaining similar terms.
- Subsequent Events: Post-March 31, the Company acquired two physician groups for approximately $15.9 million in cash.
Investor Verification Checklist
- Verify the status and shareholder approval timeline for the Magella Healthcare merger.
- Monitor the outcome of the ongoing Colorado Medicaid investigation and the federal securities class action lawsuit.
- Assess the Company's ability to refinance its $75 million line of credit maturing in September 2001.
- Review the integration costs and financial impact of the Magella merger and subsequent physician group acquisitions.